Insider transactions

EDGAR

HOMOLOGY MEDICINES, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-17.

Open-market purchases (code P)
4 transactions, 3,750,000 shares
Sum of shares × price per share: 30,000,000
Open-market sales (code S)
11 transactions, 70,338 shares
Sum of shares × price per share: 505,079.4973

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–42 of 42

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-06 Filed 2026-10-14Kalowski Lee Officer: CFO and President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,3018.3198
10,824.0598

Derived: shares × price per share. Exact value 10824.0598.

137,170Direct (D) No
F1, F2
  • F1 Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.08 to $8.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0001193125-26-421834 Read from the filing’s XML Dispute this row
2026-10-06 Filed 2026-10-14Morrison Jodie Pope Director · Officer: CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,2218.3198
26,798.0758

Derived: shares × price per share. Exact value 26798.0758.

340,038Direct (D) No
F1, F2
  • F1 Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.08 to $8.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0001193125-26-421836 Read from the filing’s XML Dispute this row
2026-10-06 Filed 2026-10-14Violette Shelia M. Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)9178.3197
7,629.1649

Derived: shares × price per share. Exact value 7629.1649.

126,854Direct (D) No
F1, F2
  • F1 Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.07 to $8.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0001193125-26-421835 Read from the filing’s XML Dispute this row
2026-08-25 Filed 2026-08-27Kalowski Lee Officer: CFO and President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,97216.56
65,776.32

Derived: shares × price per share. Exact value 65776.32.

138,471Direct (D) No
F1
  • F1 Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
Open filing 0001193125-26-371293 Read from the filing’s XML Dispute this row
2026-08-25 Filed 2026-08-27Violette Shelia M. Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,79816.56
46,334.88

Derived: shares × price per share. Exact value 46334.88.

127,771Direct (D) No
F1
  • F1 Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
Open filing 0001193125-26-371291 Read from the filing’s XML Dispute this row
2026-08-25 Filed 2026-08-27Morrison Jodie Pope Director · Officer: CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)9,84516.56
163,033.2

Derived: shares × price per share. Exact value 163033.20.

343,259Direct (D) No
F1
  • F1 Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
Open filing 0001193125-26-371292 Read from the filing’s XML Dispute this row
2026-07-16 Filed 2026-07-20Violette Shelia M. Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)37,5000—130,569Direct (D) No
F1
  • F1 Represents shares of Issuer common stock underlying performance-based restricted stock units (PSUs) granted on July 6, 2026, which vested on July 16, 2026 with respect to a performance-based condition, upon achievement of the closing of a financing of at least $100,000,000 in gross proceeds on or before December 31, 2026. Such PSUs are also subject to a time-based condition, which provides that the PSUs shall vest in equal quarterly installments over three years from July 1, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Each PSU represents a contingent right to receive one share of Issuer common stock.
Open filing 0001193125-26-309331 Read from the filing’s XML Dispute this row
2026-07-16 Filed 2026-07-20Kalowski Lee Officer: CFO and President
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)53,2500—142,443Direct (D) No
F1
  • F1 Represents shares of Issuer common stock underlying performance-based restricted stock units (PSUs) granted on July 6, 2026, which vested on July 16, 2026 with respect to a performance-based condition, upon achievement of the closing of a financing of at least $100,000,000 in gross proceeds on or before December 31, 2026. Such PSUs are also subject to a time-based condition, which provides that the PSUs shall vest in equal quarterly installments over three years from July 1, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Each PSU represents a contingent right to receive one share of Issuer common stock.
Open filing 0001193125-26-309324 Read from the filing’s XML Dispute this row
2026-07-16 Filed 2026-07-20Morrison Jodie Pope Director · Officer: CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)132,0000—353,104Direct (D) No
F1
  • F1 Represents shares of Issuer common stock underlying performance-based restricted stock units (PSUs) granted on July 6, 2026, which vested on July 16, 2026 with respect to a performance-based condition, upon achievement of the closing of a financing of at least $100,000,000 in gross proceeds on or before December 31, 2026. Such PSUs are also subject to a time-based condition, which provides that the PSUs shall vest in equal quarterly installments over three years from July 1, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Each PSU represents a contingent right to receive one share of Issuer common stock.
Open filing 0001193125-26-309327 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Manke Isaac Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)53,5212.80
149,858.8

Derived: shares × price per share. Exact value 149858.80.

53,521Direct (D) No— Open filing 0001193125-26-294694 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Manke Isaac Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (53,521) — exercise price 2.80
Disposed (D)53,5210.00
0

Derived: shares × price per share. Exact value 0.00.

0Direct (D) No
F1
  • F1 The shares underlying this option are fully vested and exercisable.
Open filing 0001193125-26-294694 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-07-21Thistle Mary Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,826) — exercise price 12.64
Acquired (A)10,8260—10,826Direct (D) No
F1, F2
  • F1 This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
  • F2 The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-310965 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-07-21TZIANABOS ARTHUR Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,826) — exercise price 12.64
Acquired (A)10,8260—10,826Direct (D) No
F1, F2
  • F1 This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
  • F2 The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-310983 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-07-21LAPORTE KATHLEEN Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,826) — exercise price 12.64
Acquired (A)10,8260—10,826Direct (D) No
F1, F2
  • F1 This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
  • F2 The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-310980 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-07-21Xu Diyong Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,826) — exercise price 12.64
Acquired (A)10,8260—10,826Direct (D) No
F1, F2, F3
  • F1 This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
  • F2 The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
  • F3 Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.
Open filing 0001193125-26-310970 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-07-21GRAYZEL DAVID S. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,826) — exercise price 12.64
Acquired (A)10,8260—10,826Direct (D) No
F1, F2, F3
  • F1 This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
  • F2 The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
  • F3 This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
Open filing 0001193125-26-310967 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-07-21Iwicki Mark T Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,826) — exercise price 12.64
Acquired (A)10,8260—10,826Direct (D) No
F1, F2
  • F1 This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
  • F2 The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-310978 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-07-21Lundberg Sven Ante Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,826) — exercise price 12.64
Acquired (A)10,8260—10,826Direct (D) No
F1, F2
  • F1 This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
  • F2 The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-310982 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-07-21Manke Isaac Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,826) — exercise price 12.64
Acquired (A)10,8260—10,826Direct (D) No
F1, F2
  • F1 This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
  • F2 The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-310969 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-16Manke Isaac Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (9,810) — exercise price 12.64
Acquired (A)9,8100—9,810Direct (D) No
F1
  • F1 The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-272698 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-16Thistle Mary Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (9,810) — exercise price 12.64
Acquired (A)9,8100—9,810Direct (D) No
F1
  • F1 The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-272690 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-16GRAYZEL DAVID S. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (9,810) — exercise price 12.64
Acquired (A)9,8100—9,810Direct (D) No
F1, F2
  • F1 The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
  • F2 This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
Open filing 0001193125-26-272692 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-16TZIANABOS ARTHUR Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (9,810) — exercise price 12.64
Acquired (A)9,8100—9,810Direct (D) No
F1
  • F1 The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-272697 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-16Iwicki Mark T Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (9,810) — exercise price 12.64
Acquired (A)9,8100—9,810Direct (D) No
F1
  • F1 The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-272700 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-16Xu Diyong Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (9,810) — exercise price 12.64
Acquired (A)9,8100—9,810Direct (D) No
F1, F2
  • F1 The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
  • F2 Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.
Open filing 0001193125-26-272686 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-16LAPORTE KATHLEEN Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (9,810) — exercise price 12.64
Acquired (A)9,8100—9,810Direct (D) No
F1
  • F1 The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-272701 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-16Lundberg Sven Ante Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (9,810) — exercise price 12.64
Acquired (A)9,8100—9,810Direct (D) No
F1
  • F1 The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-272684 Read from the filing’s XML Dispute this row
2026-05-28 Filed 2026-06-01Xu Diyong Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,250,0008.00
10,000,000

Derived: shares × price per share. Exact value 10000000.00.

3,502,987Indirect (I) See footnotesNo
F1, F2, F4
  • F1 These shares of the Issuer's common stock were purchased from the Issuer in a private placement.
  • F2 These securities are held of record by OrbiMed Private Investments VII, LP (OPI VII). OrbiMed Capital GP VII LLC (OrbiMed GP) is the general partner of OPI VII and OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.
  • F4 Each of the Reporting Person, OrbiMed Advisors, OrbiMed GP, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000594 Read from the filing’s XML Dispute this row
2026-05-28 Filed 2026-06-01Xu Diyong Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)625,0008.00
5,000,000

Derived: shares × price per share. Exact value 5000000.00.

625,000Indirect (I) See footnotesNo
F1, F3, F4
  • F1 These shares of the Issuer's common stock were purchased from the Issuer in a private placement.
  • F3 These securities are held of record by OrbiMed Genesis Master Fund, L.P. (Genesis). OrbiMed Genesis GP LLC (Genesis GP) is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
  • F4 Each of the Reporting Person, OrbiMed Advisors, OrbiMed GP, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000594 Read from the filing’s XML Dispute this row
2026-05-28 Filed 2026-06-01ORBIMED ADVISORS LLC Director · 10% ownerOrbiMed Capital GP VII LLC Director · 10% ownerOrbiMed Genesis GP LLC Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,250,0008.00
10,000,000

Derived: shares × price per share. Exact value 10000000.00.

3,502,987Indirect (I) See footnotesNo
F1, F2, F4
  • F1 These shares of the Issuer's common stock were purchased from the Issuer in a private placement.
  • F2 These securities are held of record by OrbiMed Private Investments VII, LP (OPI VII). OrbiMed Capital GP VII LLC (OrbiMed GP) is the general partner of OPI VII and OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors, OrbiMed GP, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Diyong Xu, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000593 Read from the filing’s XML Dispute this row
2026-05-28 Filed 2026-06-01ORBIMED ADVISORS LLC Director · 10% ownerOrbiMed Capital GP VII LLC Director · 10% ownerOrbiMed Genesis GP LLC Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)625,0008.00
5,000,000

Derived: shares × price per share. Exact value 5000000.00.

625,000Indirect (I) See footnotesNo
F1, F3, F4
  • F1 These shares of the Issuer's common stock were purchased from the Issuer in a private placement.
  • F3 These securities are held of record by OrbiMed Genesis Master Fund, L.P. (Genesis). OrbiMed Genesis GP LLC (Genesis GP) is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors, OrbiMed GP, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Diyong Xu, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Open filing 0000947871-26-000593 Read from the filing’s XML Dispute this row
2026-02-25 Filed 2026-02-27Violette Shelia M. Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,8154.5144
12,708.036

Derived: shares × price per share. Exact value 12708.0360.

55,569Direct (D) No
F1, F2
  • F1 Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.35 to $4.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0001193125-26-083584 Read from the filing’s XML Dispute this row
2026-02-25 Filed 2026-02-27Kalowski Lee Officer: CFO and President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,9954.5144
18,035.028

Derived: shares × price per share. Exact value 18035.0280.

35,943Direct (D) No
F1, F2
  • F1 Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.35 to $4.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0001193125-26-083588 Read from the filing’s XML Dispute this row
2026-02-25 Filed 2026-02-27Morrison Jodie Pope Director · Officer: CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)9,8964.5144
44,674.5024

Derived: shares × price per share. Exact value 44674.5024.

89,104Direct (D) No
F1, F2
  • F1 Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
  • F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.35 to $4.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open filing 0001193125-26-083585 Read from the filing’s XML Dispute this row
2026-02-24 Filed 2026-03-20Kalowski Lee Officer: CFO and President
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)53,2500—89,193Direct (D) No
F1
  • F1 The restricted stock units (RSUs) vest in four equal installments, 25% shall vest 6 months from February 24, 2026 (the Grant Date), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock.
Open filing 0001193125-26-118052 Read from the filing’s XML Dispute this row
2026-02-24 Filed 2026-03-20Morrison Jodie Pope Director · Officer: CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)132,0000—221,104Direct (D) No
F1
  • F1 The restricted stock units (RSUs) vest in four equal installments, 25% shall vest 6 months from February 24, 2026 (the Grant Date), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock.
Open filing 0001193125-26-118053 Read from the filing’s XML Dispute this row
2026-02-24 Filed 2026-03-20Violette Shelia M. Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)37,5000—93,069Direct (D) No
F1
  • F1 The restricted stock units (RSUs) vest in four equal installments, 25% shall vest 6 months from February 24, 2026 (the Grant Date), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock.
Open filing 0001193125-26-118054 Read from the filing’s XML Dispute this row
2026-01-15 Filed 2026-01-30GRAYZEL DAVID S. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (16,363) — exercise price 3.60
Acquired (A)16,3632.75
44,998.25

Derived: shares × price per share. Exact value 44998.25.

16,363Direct (D) No
F1, F2
  • F1 This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees. Due to administrative oversight this option award initially was not reported.
  • F2 This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
Open filing 0001193125-26-032247 Read from the filing’s XML Dispute this row
2026-01-15 Filed 2026-01-30Lundberg Sven Ante Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (20,363) — exercise price 3.60
Acquired (A)20,3632.75
55,998.25

Derived: shares × price per share. Exact value 55998.25.

20,363Direct (D) No
F1
  • F1 This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees. Due to administrative oversight this option award initially was not reported.
Open filing 0001193125-26-032246 Read from the filing’s XML Dispute this row
2026-01-15 Filed 2026-01-30LAPORTE KATHLEEN Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (23,272) — exercise price 3.60
Acquired (A)23,2722.75
63,998

Derived: shares × price per share. Exact value 63998.00.

23,272Direct (D) No
F1
  • F1 This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees. Due to administrative oversight this option award initially was not reported.
Open filing 0001193125-26-032248 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-04Morrison Jodie Pope Director · Officer: CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)22,5063.46
77,870.76

Derived: shares × price per share. Exact value 77870.76.

99,000Direct (D) No— Open filing 0001193125-25-308328 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-04Kalowski Lee Officer: CFO and President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)9,0723.4607
31,395.4704

Derived: shares × price per share. Exact value 31395.4704.

39,938Direct (D) No— Open filing 0001193125-25-308327 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 7,211 filings read, the latest filed 2026-11-13. Prior quarter ending 2026-06-30: 9,150 filings read.

Showing 1–50 of 63

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Atlas Venture Life Science Advisors, LLC 2,717,106 SH22,470,467 dollarsUnchanged Prior quarter: 2,717,106Open filing 0001104659-26-125242 Filed 2026-11-10 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager1,062,137 SH10,122,166 dollarsNot in the prior quarter’s filings read Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 1,008,451 SH8,339,890 dollarsHigher by 489,648 Prior quarter: 518,803Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
AMERICAN CENTURY COMPANIES INC Partly reported under another manager652,597 SH5,396,977 dollarsHigher by 379,845 Prior quarter: 272,752Open filing 0000748054-26-000008 Filed 2026-11-12 Dispute this row
Qube Research Technologies Ltd 381,469 SH3,154,749 dollarsNot in the prior quarter’s filings read Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row
MARSHALL WACE, LLP Partly reported under another manager368,935 SH3,051,093 dollarsHigher by 301,890 Prior quarter: 67,045Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row
BlackRock, Inc. Partly reported under another manager340,353 SH2,814,719 dollarsHigher by 221,846 Prior quarter: 118,507Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
Aberdeen Group plc Partly reported under another manager302,500 SH2,501,675 dollarsNot in the prior quarter’s filings read Open filing 0001716774-26-000032 Filed 2026-11-10 Dispute this row
Sanofi 244,083 SH2,018,566 dollarsUnchanged Prior quarter: 244,083Open filing 0001193125-26-448717 Filed 2026-11-05 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager240,954 SH1,993,746 dollarsHigher by 118,264 Prior quarter: 122,690Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Squarepoint Ops LLC Partly reported under another manager192,095 SH1,588,626 dollarsHigher by 168,305 Prior quarter: 23,790Open filing 0001642575-26-000012 Filed 2026-11-09 Dispute this row
TD ASSET MANAGEMENT INC 190,332 SH1,813,864 dollarsNot in the prior quarter’s filings read Open filing 0001193125-26-460060 Filed 2026-11-13 Dispute this row
Walleye Capital LLC 182,428 SH1,508,680 dollarsNot in the prior quarter’s filings read Open filing 0001758720-26-000007 Filed 2026-11-13 Dispute this row
UBS Group AG Partly reported under another manager164,470 SH1,360,167 dollarsHigher by 149,462 Prior quarter: 15,008Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
JANE STREET GROUP, LLC Partly reported under another manager160,819 SH1,329,973 dollarsLower by 1,928 Prior quarter: 162,747Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
VANGUARD FIDUCIARY TRUST CO 130,341 SH1,077,920 dollarsHigher by 64,124 Prior quarter: 66,217Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager120,897 SH998 dollarsLower by 97,337 Prior quarter: 218,234Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager110,331 SH912,438 dollarsHigher by 86,743 Prior quarter: 23,588Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
MANUFACTURERS LIFE INSURANCE COMPANY, THE Partly reported under another manager107,804 SH891,539 dollarsNot in the prior quarter’s filings read Open filing 0001145443-26-000111 Filed 2026-11-13 Dispute this row
Nutshell Asset Management Ltd 98,299 SH812,933 dollarsNot in the prior quarter’s filings read Open filing 0002021442-26-000006 Filed 2026-11-13 Dispute this row
FIRST TRUST ADVISORS LP 89,134 SH737,138 dollarsNot in the prior quarter’s filings read Open filing 0001445546-26-008622 Filed 2026-11-12 Dispute this row
STATE STREET CORP Partly reported under another manager88,114 SH728,703 dollarsHigher by 35,900 Prior quarter: 52,214Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP Partly reported under another manager75,515 SH624,509 dollarsNot in the prior quarter’s filings read Open filing 0001164508-26-000060 Filed 2026-11-13 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager69,800 SH577,246 dollarsLower by 109,800 Prior quarter: 179,600Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
MORGAN STANLEY Partly reported under another manager60,630 SH501,410 dollarsHigher by 54,174 Prior quarter: 6,456Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
Fisher Asset Management, LLC Partly reported under another manager37,261 SH308,148 dollarsNot in the prior quarter’s filings read Open filing 0000850529-26-000009 Filed 2026-11-06 Dispute this row
Stonepine Capital Management, LLC 31,200 SH258,024 dollarsNot in the prior quarter’s filings read Open filing 0001440771-26-000027 Filed 2026-11-13 Dispute this row
Integrated Quantitative Investments LLC 28,438 SH235,182 dollarsNot in the prior quarter’s filings read Open filing 0001941040-26-000818 Filed 2026-11-13 Dispute this row
Affinity Asset Advisors, LLC 27,777 SH229,716 dollarsUnchanged Prior quarter: 27,777Open filing 0001011438-26-000687 Filed 2026-11-13 Dispute this row
FOX RUN MANAGEMENT, L.L.C. 22,193 SH183,536 dollarsNot in the prior quarter’s filings read Open filing 0001420506-26-002585 Filed 2026-11-12 Dispute this row
LPL Financial LLC 15,176 SH125,506 dollarsLower by 2,994 Prior quarter: 18,170Open filing 0001403438-26-000005 Filed 2026-11-06 Dispute this row
Jump Financial, LLC Partly reported under another manager13,292 SH109,925 dollarsNot in the prior quarter’s filings read Open filing 0000905148-26-004786 Filed 2026-11-13 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager13,093 SH108,279 dollarsNot in the prior quarter’s filings read Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
DCF Advisers, LLC 13,000 SH107,510 dollarsNot in the prior quarter’s filings read Open filing 0001013594-26-001138 Filed 2026-11-04 Dispute this row
JANE STREET GROUP, LLC Option: Put Partly reported under another manager12,300 SH101,721 dollarsNot in the prior quarter’s filings read Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
Yorkville Advisors Global, LP 10,000 SH82,700 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-126193 Filed 2026-11-12 Dispute this row
Aster Capital Management (DIFC) Ltd Partly reported under another manager9,817 SH81,187 dollarsNot in the prior quarter’s filings read Open filing 0002040915-26-000006 Filed 2026-11-12 Dispute this row
BOLTON SECURITIES CORPORATION 8,000 SH66,160 dollarsLower by 2,000 Prior quarter: 10,000Open filing 0001457457-26-000016 Filed 2026-11-12 Dispute this row
Vanguard Global Advisers, LLC 7,848 SH64,903 dollarsHigher by 3,024 Prior quarter: 4,824Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row
BARCLAYS PLC Partly reported under another manager7,841 SH64,845 dollarsNot in the prior quarter’s filings read Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
US BANCORP \DE\ Partly reported under another manager6,093 SH50,389 dollarsNot in the prior quarter’s filings read Open filing 0000036104-26-000059 Filed 2026-11-05 Dispute this row
FMR LLC Partly reported under another manager3,115 SH25,761 dollarsLower by 273 Prior quarter: 3,388Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
CITIGROUP INC Partly reported under another manager2,823 SH23,346 dollarsLower by 65 Prior quarter: 2,888Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
SIMPLEX TRADING, LLC Option: Put 1,700 SH14,059 dollarsHigher by 1,500 Prior quarter: 200Open filing 0001488542-26-000013 Filed 2026-11-04 Dispute this row
SIMPLEX TRADING, LLC 1,582 SH13,083 dollarsNot in the prior quarter’s filings read Open filing 0001488542-26-000013 Filed 2026-11-04 Dispute this row
Steward Partners Investment Advisory, LLC 871 SH7,203 dollarsNot in the prior quarter’s filings read Open filing 0001723397-26-000006 Filed 2026-11-13 Dispute this row
JONES FINANCIAL COMPANIES LLLP Partly reported under another manager664 SH5,823 dollarsHigher by 164 Prior quarter: 500Open filing 0001193125-26-459442 Filed 2026-11-13 Dispute this row
Rockefeller Capital Management L.P. Partly reported under another manager577 SH4,772 dollarsUnchanged Prior quarter: 577Open filing 0001739439-26-000009 Filed 2026-11-13 Dispute this row
Russell Investments Group, Ltd. Partly reported under another manager454 SH3,755 dollarsUnchanged Prior quarter: 454Open filing 0001193125-26-451241 Filed 2026-11-06 Dispute this row
Nuveen, LLC Partly reported under another manager317 SH472 dollarsNot in the prior quarter’s filings read Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • ORBIMED ADVISORS LLC 4,127,987 SH
  • Boxer Capital Management, LLC 3,149,310 SH
  • BVF INC/IL 2,350,000 SH
  • RA CAPITAL MANAGEMENT, L.P. 2,332,457 SH
  • Point72 Asset Management, L.P. 1,173,396 SH
  • Opaleye Management Inc. 931,000 SH
  • Logos Global Management LP 800,000 SH
  • SummitTX Capital, L.P. 733,774 SH
  • Ikarian Capital, LLC 430,000 SH
  • Woodline Partners LP 286,212 SH
  • ACORN CAPITAL ADVISORS, LLC 216,171 SH
  • Ikarian Capital, LLC 200,000 SH
  • MONIMUS CAPITAL MANAGEMENT, LP 132,036 SH
  • BOOTHBAY FUND MANAGEMENT, LLC 130,427 SH
  • CITADEL ADVISORS LLC 120,663 SH
  • BOOTHBAY FUND MANAGEMENT, LLC 61,300 SH
  • Carlyle Group Inc. 60,363 SH
  • TWO SIGMA INVESTMENTS, LP 49,582 SH
  • Quadrature Capital Ltd 36,396 SH
  • Cambridge Investment Research Advisors, Inc. 36,162 SH
  • BRIDGEWAY CAPITAL MANAGEMENT, LLC 34,613 SH
  • DAFNA Capital Management LLC 32,896 SH
  • Knott David M Jr 30,412 SH
  • NORTHERN TRUST CORP 23,631 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 23,342 SH
  • MANGROVE PARTNERS IM, LLC 22,150 SH
  • HRT FINANCIAL LP 15,949 SH
  • Balyasny Asset Management L.P. 12,342 SH
  • ExodusPoint Capital Management, LP 11,336 SH
  • MILLENNIUM MANAGEMENT LLC 10,928 SH
  • XTX Topco Ltd 10,874 SH
  • Private Wealth Asset Management, LLC 1,700 SH
  • Arax Advisory Partners 1,111 SH
  • FEDERATED HERMES, INC. 1,050 SH
  • KERR FINANCIAL PLANNING Corp 600 SH
  • Truvestments Capital LLC 162 SH
  • Federation des caisses Desjardins du Quebec 70 SH
  • Caitong International Asset Management Co., Ltd 45 SH
  • ROYAL BANK OF CANADA 43 SH
  • GROUP ONE TRADING LLC 34 SH
  • AdvisorNet Financial, Inc 2 SH
  • MERCER GLOBAL ADVISORS INC /ADV 2 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Frazier Life Sciences Public Fund, L.P. Common Stock, $0.00001 par value5.91,755,116.0010/02/2026 Filed 2026-10-09SCHEDULE 13GOpen filing 0001231919-26-001441 Dispute this row
FHMLSP, L.P. Common Stock, $0.00001 par value5.91,755,116.0010/02/2026 Filed 2026-10-09SCHEDULE 13GOpen filing 0001231919-26-001441 Dispute this row
FHMLSP, L.L.C. Common Stock, $0.00001 par value5.91,755,116.0010/02/2026 Filed 2026-10-09SCHEDULE 13GOpen filing 0001231919-26-001441 Dispute this row
Frazier Life Sciences XI, L.P. Common Stock, $0.00001 par value0.123,029.0010/02/2026 Filed 2026-10-09SCHEDULE 13GOpen filing 0001231919-26-001441 Dispute this row
FHMLS XI, L.P. Common Stock, $0.00001 par value0.123,029.0010/02/2026 Filed 2026-10-09SCHEDULE 13GOpen filing 0001231919-26-001441 Dispute this row
FHMLS XI, L.L.C. Common Stock, $0.00001 par value0.123,029.0010/02/2026 Filed 2026-10-09SCHEDULE 13GOpen filing 0001231919-26-001441 Dispute this row
Frazier Life Sciences XII, L.P. Common Stock, $0.00001 par value0.4125,039.0010/02/2026 Filed 2026-10-09SCHEDULE 13GOpen filing 0001231919-26-001441 Dispute this row
FHMLS XII, L.P. Common Stock, $0.00001 par value0.4125,039.0010/02/2026 Filed 2026-10-09SCHEDULE 13GOpen filing 0001231919-26-001441 Dispute this row
FHMLS XII, L.L.C. Common Stock, $0.00001 par value0.4125,039.0010/02/2026 Filed 2026-10-09SCHEDULE 13GOpen filing 0001231919-26-001441 Dispute this row
Boxer Capital Management, LLC Common Stock, $0.0001 par value per share7.92,357,922.0009/30/2026 Filed 2026-11-06SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-116951 Dispute this row
Boxer Holdings, LP Common Stock, $0.0001 par value per share7.92,357,922.0009/30/2026 Filed 2026-11-06SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-116951 Dispute this row
Boxer Holdings GP, LLC Common Stock, $0.0001 par value per share7.92,357,922.0009/30/2026 Filed 2026-11-06SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-116951 Dispute this row
Aaron Davis Common Stock, $0.0001 par value per share7.92,357,922.0009/30/2026 Filed 2026-11-06SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-116951 Dispute this row
Opaleye Management Inc. Common Stock, par value $0.0001 per share3.761,120,000.0009/30/2026 Filed 2026-11-06SCHEDULE 13G/AAmendment 3Open filing 0001493152-26-050448 Dispute this row
Opaleye, L.P. Common Stock, par value $0.0001 per share3.761,120,000.0009/30/2026 Filed 2026-11-06SCHEDULE 13G/AAmendment 3Open filing 0001493152-26-050448 Dispute this row
James Silverman Common Stock, par value $0.0001 per share3.761,120,000.0009/30/2026 Filed 2026-11-06SCHEDULE 13G/AAmendment 3Open filing 0001493152-26-050448 Dispute this row
BANK OF AMERICA CORP /DE/ Common Stock7.42,205,390.0009/30/2026 Filed 2026-10-28SCHEDULE 13GOpen filing 0000070858-26-000536 Dispute this row
ORBIMED ADVISORS LLC COMMON STOCK13.94,127,987.0007/16/2026 Filed 2026-07-20SCHEDULE 13D/AAmendment 4Open filing 0000947871-26-000713 Dispute this row
ORBIMED CAPITAL GP VII LLC COMMON STOCK11.83,502,987.0007/16/2026 Filed 2026-07-20SCHEDULE 13D/AAmendment 4Open filing 0000947871-26-000713 Dispute this row
OrbiMed Genesis GP LLC COMMON STOCK2.1625,000.0007/16/2026 Filed 2026-07-20SCHEDULE 13D/AAmendment 4Open filing 0000947871-26-000713 Dispute this row
Point72 Asset Management, L.P. Common Stock, par value $0.0001 per share4.951,173,396.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000919574-26-005496 Dispute this row
Point72 Capital Advisors, Inc. Common Stock, par value $0.0001 per share4.951,173,396.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000919574-26-005496 Dispute this row
Steven A. Cohen Common Stock, par value $0.0001 per share4.951,173,396.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000919574-26-005496 Dispute this row
Sirenia Capital Management LP Common Stock, par value $0.0001 per share00.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-005207 Dispute this row
Alex Silverstein Common Stock, par value $0.0001 per share00.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-005207 Dispute this row
Opaleye Management Inc. Common Stock, par value $0.0001 per share5.49931,000.0006/30/2026 Filed 2026-07-31SCHEDULE 13G/AAmendment 2Open filing 0001493152-26-035622 Dispute this row
Opaleye, L.P. Common Stock, par value $0.0001 per share5.49931,000.0006/30/2026 Filed 2026-07-31SCHEDULE 13G/AAmendment 2Open filing 0001493152-26-035622 Dispute this row
James Silverman Common Stock, par value $0.0001 per share5.49931,000.0006/30/2026 Filed 2026-07-31SCHEDULE 13G/AAmendment 2Open filing 0001493152-26-035622 Dispute this row
Boxer Capital Management, LLC Common Stock, $0.0001 par value per share13.303,149,310.0006/30/2026 Filed 2026-07-10SCHEDULE 13GOpen filing 0001213900-26-077181 Dispute this row
Boxer Holdings, LP Common Stock, $0.0001 par value per share13.303,149,310.0006/30/2026 Filed 2026-07-10SCHEDULE 13GOpen filing 0001213900-26-077181 Dispute this row
Boxer Holdings GP, LLC Common Stock, $0.0001 par value per share13.303,149,310.0006/30/2026 Filed 2026-07-10SCHEDULE 13GOpen filing 0001213900-26-077181 Dispute this row
Aaron Davis Common Stock, $0.0001 par value per share13.303,149,310.0006/30/2026 Filed 2026-07-10SCHEDULE 13GOpen filing 0001213900-26-077181 Dispute this row
The Carlyle Group Inc. Common Stock, par value $0.0001 per share4.1691,735.0006/30/2026 Filed 2026-07-06SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-032227 Dispute this row
Carlyle Holdings I GP Inc. Common Stock, par value $0.0001 per share4.1691,735.0006/30/2026 Filed 2026-07-06SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-032227 Dispute this row
Carlyle Holdings I GP Sub L.L.C. Common Stock, par value $0.0001 per share4.1691,735.0006/30/2026 Filed 2026-07-06SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-032227 Dispute this row
Carlyle Holdings I L.P. Common Stock, par value $0.0001 per share4.1691,735.0006/30/2026 Filed 2026-07-06SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-032227 Dispute this row
CG Subsidiary Holdings L.L.C. Common Stock, par value $0.0001 per share4.1691,735.0006/30/2026 Filed 2026-07-06SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-032227 Dispute this row
TC Group, L.L.C. Common Stock, par value $0.0001 per share4.1691,735.0006/30/2026 Filed 2026-07-06SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-032227 Dispute this row
Carlyle Investment Management L.L.C. Common Stock, par value $0.0001 per share4.1691,735.0006/30/2026 Filed 2026-07-06SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-032227 Dispute this row
Carlyle Genesis UK LLC Common Stock, par value $0.0001 per share4.1691,735.0006/30/2026 Filed 2026-07-06SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-032227 Dispute this row
Abingworth LLP Common Stock, par value $0.0001 per share4.1691,735.0006/30/2026 Filed 2026-07-06SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-032227 Dispute this row
Abingworth Bioventures VII LP Common Stock, par value $0.0001 per share4.1691,735.0006/30/2026 Filed 2026-07-06SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-032227 Dispute this row
RA Capital Management, L.P. Common Stock, par value $0.0001 per share9.82,332,457.0005/28/2026 Filed 2026-06-04SCHEDULE 13GOpen filing 0001346824-26-000170 Dispute this row
Peter Kolchinsky Common Stock, par value $0.0001 per share9.82,332,457.0005/28/2026 Filed 2026-06-04SCHEDULE 13GOpen filing 0001346824-26-000170 Dispute this row
Rajeev Shah Common Stock, par value $0.0001 per share9.82,332,457.0005/28/2026 Filed 2026-06-04SCHEDULE 13GOpen filing 0001346824-26-000170 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, par value $0.0001 per share9.82,332,457.0005/28/2026 Filed 2026-06-04SCHEDULE 13GOpen filing 0001346824-26-000170 Dispute this row
BIOTECHNOLOGY VALUE FUND L P Common Stock, par value $0.0001 per share5.31,248,973.0005/28/2026 Filed 2026-06-04SCHEDULE 13GOpen filing 0000921895-26-001559 Dispute this row
BVF I GP LLC Common Stock, par value $0.0001 per share5.31,248,973.0005/28/2026 Filed 2026-06-04SCHEDULE 13GOpen filing 0000921895-26-001559 Dispute this row
BIOTECHNOLOGY VALUE FUND II LP Common Stock, par value $0.0001 per share3.9929,003.0005/28/2026 Filed 2026-06-04SCHEDULE 13GOpen filing 0000921895-26-001559 Dispute this row
BVF II GP LLC Common Stock, par value $0.0001 per share3.9929,003.0005/28/2026 Filed 2026-06-04SCHEDULE 13GOpen filing 0000921895-26-001559 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,119,757 filings read, dated 2004-06-14 to 2026-11-13: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202242,927
2023199,811
2024209,823
2025235,520
2026254,737

Filings made before the SEC required XML are listed, not extracted.

Back to HOMOLOGY MEDICINES, INC.